1. Home
  2. GDL vs CRDL Comparison

GDL vs CRDL Comparison

Compare GDL & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GDL Fund The of Beneficial Interest

GDL

GDL Fund The of Beneficial Interest

HOLD

Current Price

$8.34

Market Cap

90.7M

Sector

Finance

ML Signal

HOLD

Logo Cardiol Therapeutics Inc.

CRDL

Cardiol Therapeutics Inc.

HOLD

Current Price

$1.31

Market Cap

97.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GDL
CRDL
Founded
2006
2017
Country
United States
Canada
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
90.7M
97.3M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
GDL
CRDL
Price
$8.34
$1.31
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$8.67
AVG Volume (30 Days)
10.1K
996.7K
Earning Date
01-01-0001
05-13-2026
Dividend Yield
6.02%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.81
$0.85
52 Week High
$8.67
$1.59

Technical Indicators

Market Signals
Indicator
GDL
CRDL
Relative Strength Index (RSI) 55.50 62.55
Support Level $8.39 $0.95
Resistance Level $8.47 $1.40
Average True Range (ATR) 0.10 0.11
MACD 0.01 0.03
Stochastic Oscillator 67.12 70.83

Price Performance

Historical Comparison
GDL
CRDL

About GDL GDL Fund The of Beneficial Interest

GDL Fund is a diversified closed-end management investment company. Its primary investment objective is to achieve absolute returns in various market conditions without excessive risk of capital. The fund seeks to achieve its objective by investing in merger arbitrage transactions and, to a lesser extent, in corporate reorganizations involving stubs, spin-offs, and liquidations.

About CRDL Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.

Share on Social Networks: